Search

Your search keyword '"Ling, Yesheng"' showing total 30 results
Start Over Author "Ling, Yesheng"
30 results on '"Ling, Yesheng"'

3. LASSO Regression-Based Diagnosis of Acute ST-Segment Elevation Myocardial Infarction (STEMI) on Electrocardiogram (ECG)

Author

Wu, Lin, primary, Zhou, Bin, additional, Liu, Dinghui, additional, Wang, Linli, additional, Zhang, Ximei, additional, Xu, Li, additional, Yuan, Lianxiong, additional, Zhang, Hui, additional, Ling, Yesheng, additional, Shi, Guangyao, additional, Ke, Shiye, additional, He, Xuemin, additional, Tian, Borui, additional, Chen, Yanming, additional, and Qian, Xiaoxian, additional

Published
2022
Full Text
View/download PDF

5. Deep Learning Networks Accurately Detect ST-Segment Elevation Myocardial Infarction and Culprit Vessel

Author

Wu, Lin, primary, Huang, Guifang, additional, Yu, Xianguan, additional, Ye, Minzhong, additional, Liu, Lu, additional, Ling, Yesheng, additional, Liu, Xiangyu, additional, Liu, Dinghui, additional, Zhou, Bin, additional, Liu, Yong, additional, Zheng, Jianrui, additional, Liang, Suzhen, additional, Pu, Rui, additional, He, Xuemin, additional, Chen, Yanming, additional, Han, Lanqing, additional, and Qian, Xiaoxian, additional

Published
2022
Full Text
View/download PDF

29. Alirocumab effect on preventing periprocedural ischaemic events in coronary heart disease patients undergoing coronary stenting (APPEASE trial): study protocol of a multicentre, open-label, randomised controlled trial.

Author

Huang Z, Zhuang X, Zhang S, Huang Y, Yuan L, Lin A, Tang L, Xiong Z, Christopher O, Chen Y, Wu B, Ling Y, Li S, Jie Q, Xiong L, Qian X, Liao X, and Liu J

Subjects
Humans, Antibodies, Monoclonal, Humanized therapeutic use, Randomized Controlled Trials as Topic, Multicenter Studies as Topic, Percutaneous Coronary Intervention, Coronary Disease complications, Coronary Disease surgery, Myocardial Infarction
Abstract

Introduction: Percutaneous coronary intervention (PCI)-related myocardial infarction (type 4a MI) and major periprocedural myocardial injury have been demonstrated leading to poor prognosis of patients with coronary heart disease (CHD) undergoing elective PCI and still remain high occurrence even after the therapy of dual antiplatelet agents and statins. Proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab has been shown to be effectively in reducing the risk of acute MI (AMI). However, the effect of alirocumab on preventing PCI-related MI or major periprocedural myocardial injury in patients with CHD undergoing elective PCI remains uncertain., Methods and Analysis: Alirocumab effect on Preventing Periprocedural ischaemic Events in coronary heart diseAse patients undergoing coronary StEnting trial is a multicentre, open-label, randomised controlled trial aiming to determine whether alirocumab could reduce the incidence of type 4a MI or major periprocedural myocardial injury in patients with CHD undergoing elective PCI. In total, 422 non-AMI CHD patients planned to undergo elective PCI will be randomly assigned to receive standard pharmacotherapy of CHD (control group) or additional use of subcutaneous alirocumab 75 mg 1 day before procedure (alirocumab group). The primary outcome is type 4a MI or major periprocedural myocardial injury defined as high-sensitivity cardiac troponin elevating above 5×99 th percentile upper reference limit in 48 hours after PCI. Patients will continue receiving standard pharmacotherapy or additional biweekly subcutaneous alirocumab 75 mg for 3 months according to the initial randomisation group. We will follow up for 3 months and record all the major adverse cardiovascular events (MACEs). Incidence of PCI-related MI or major periprocedural myocardial injury, and MACE in 3 months after PCI will be compared between control group and alirocumab group., Ethics and Dissemination: Ethics approval has been obtained from the Medical Ethics Committee of the Third Affiliated Hospital of Sun Yat-sen University with approval number: (2022)02-140-01. The results of this study will be reported through peer-reviewed journals and conference presentations., Trial Registration Number: ChiCTR2200063191., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2023
Full Text
View/download PDF

30. Long noncoding RNA SRA1 attenuates hypoxia-induced injury in H9c2 cardiomyocytes through regulating PPARγ/NF-κB signaling pathway.

Author

Zhang C, Pan S, Aisha A, Abudoukelimu M, Tang L, and Ling Y

Abstract

This study aimed to investigate the effects and mechanisms of long noncoding RNA SRA1 on regulating hypoxia-induced injury in H9c2 cardiomyocytes. The H9c2 cardiomyocytes were cultured under hypoxic (3% O 2 ) conditions and whether hypoxia induced injury was assessed by detecting cell viability, apoptosis and autophagy. Then, SRA1 was overexpressed and suppressed in H9c2 cardiomyocytes by transfection with pc-SRA1 and sh-SRA1, and the effects of SRA1 dysregulation on cell viability, apoptosis, and autophagy of H9c2 cardiomyocytes under hypoxia condition were detected. Furthermore, the regulatory relationship between SRA1 and PPARγ was explored, as well as the association between SRA1 and NF-κB signaling. Hypoxia induced injury to H9c2 cardiomyocytes, such as inhibiting cell viability, and promoting cell apoptosis and autophagy. Moreover, hypoxia resulted in a decreased expression of SRA1 in H9c2 cardiomyocytes, and overexpression of SRA1 alleviated hypoxia-induced injury, while suppression of SRA1 indicated the contrary results. Further studies showed that SRA1 positively regulated PPARγ. Overexpression of SRA1 alleviated hypoxia injury by activating PPARγ. Besides, suppression of SRA1 activated NF-κB pathway in hypoxia-treated H9c2 cardiomyocytes, which were significantly reversed after suppression of SRA1 and overexpression of PPARγ at the same time. Our findings indicated that suppression of SRA1 may aggravate hypoxia-induced injury to H9c2 cardiomyocytes by positive regulation of PPARγ and activation of NF-κB pathway. SRA1 may serve as a promising perspective for the therapy of heart failure induced by hypoxia., Competing Interests: None., (IJCEP Copyright © 2018.)

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results